PHG

PHG

USD

Koninklijke Philips N.V. NY Registry Shares

$28.020-0.180 (-0.638%)

Precio en Tiempo Real

Healthcare
Dispositivos médicos
Países Bajos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$28.200

Máximo

$28.525

Mínimo

$27.830

Volumen

1.00M

Fundamentos de la Empresa

Capitalización de Mercado

26.9B

Industria

Dispositivos médicos

País

Netherlands

Estadísticas de Negociación

Volumen Promedio

0.74M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $21.48Actual $28.020Máximo $29.29

Noticias Relacionadas

GlobeNewswire

Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion

November 4, 2025Q3 2025 Group Highlights Comparable order intake growth 8%Group sales amounted to EUR 4.3 billion, reflecting 3% increase in comparable salesIncome from operations was EUR 330 millionAdjusted EBITA

Ver más
Philips continues momentum; delivers strong order intake, step-up in sales growth and margin expansion
BusinessWire

Philips Joins the Forever Promise Project to Honor American Veterans

Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced its support of the Forever Promise Project, an initiative of the Monuments Men and Women Foundation that connects American

Ver más
Philips Joins the Forever Promise Project to Honor American Veterans
GlobeNewswire

Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA

October 30, 2025 10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport

Ver más
Hoag selects Philips to enhance and unify patient monitoring, elevating care across Orange County, USA
GlobeNewswire

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant difference in major

Ver más
Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.